WTEC Panel Report on
Tissue Engineering Research
Larry V. McIntire (Panel chair)
Howard P. Greisler
Linda Griffith
Peter C. Johnson
David J. Mooney
Milan Mrksich
Nancy L. Parenteau
David Smith
January 2002
The final report is available in Adobe Acrobat (pdf) format. The entire
report is approximately 1.8 MB. The Executive Summary (included in the entire
report) is also available as a separate file.
Table of Contents
Foreword
List of Figures
List of Tables
Executive Summary
1. Introduction
Larry V. McIntire
- Background: The Significance of Tissue Engineering
- History of Tissue Engineering
- Promise of Tissue Engineering
- Other Applications
- Emerging Industry of Tissue Engineering
- Objectives of the WTEC Study
- Scope and Methodology
- Vision for the Future
- Acknowledgements
- References
2. Biomaterials
Linda G. Griffith
- Introduction
- U.S. R&D Activities
- Japanese R&D
Activities
- European R&D
Activities
- Summary
- References
3. Cells
Nancy L. Parenteau
- Introduction
- Analysis of Current State of the Art
and Factors Influencing Progress
- Control of cell proliferation and
differentiation
- U.S. R&D Activities
- Background
- Current EFFORTS
- Future position
- R&D Activities in
EUROPE
- Japan
- Summary
- References
4. Biomolecules
Howard P. Greisler
- Introduction
- Gene Transfer
- Angiogenic Factors/Growth
Factors
- Differentiation Factors
- Bone MorphoGenic Proteins
- References
5. Cell-Based Technologies: Non-Medical
Applications
Milan Mrksich
- Introduction
- Overview of R&D
Activities
- Summary
6. Engineering Design Aspects of Tissue
Engineering
David Mooney
- Introduction
- Bioreactor Technology
- Preservation of Cells and Engineered
Tissues
- Mass Transport Issues Following
Implantation
- Biomechanics Issues
- Summary
- References
7. Informatics and Tissue Engineering
Peter C. Johnson
- Introduction
- Informatics Components That Will
Ultimately Support Tissue Engineering
- U.S. R&D Activities
- European R&D
Activities
- Japanese R&D
Activities
- Summary
- References
8. Legal and Regulatory Issues
David Smith
- Introduction
- FDA Regulation
- Other Considerations Relevant to
Engineered Tissues
- Regulation of Pharmaceutical/Medical
Human Tissue Products in Europe
- Regulation of Pharmaceutical/Medical
Human Tissue Products in Japan
- Conclusion
- References
Appendices
A. Biographies of Panelists
B. Site Reports-Europe
- bwA, Aachen Centre of Competence: Biomaterials
- Cell Lining GmbH
- Berlin Workshop
- ERA Consulting (UK), Ltd.
- ETH Zurich
- European Agency for the Evaluation
of Medicinal Products (EMEA)
- European Molecular Biology
Laboratory (EMBL)
- German Cancer Research Center
(DKFZ)
- German Heart Institute
- Humboldt University of Berlin,
Charité
- Biomaterial and Tissue Repair
Laboratory (INSERM)
- Imperial College of Science,
Technology and Medicine
- Imperial College of Science,
Technology and Medicine
- University of Glasgow
- IsoTis (technical report)
- IsoTis (regulatory report)
- Kirchhoff Institute of Physics
(KIP)
- Manchester University
- Max Planck Institute for Polymer
Research
- MeVis
- Smith & Nephew Group Research
Centre
- University of Freiburg
- University of Koln
- University of Regensburg
- University of Twente
C. Site Reports-Japan
- Hokkaido University
- Japan Tissue Engineering Company,
Ltd.
- Keio University
- Kyoto University
- Kyushu University
- Nippon Telegraph and Telephone
Corporation (NTT) Basic Research Laboratories
- Nagoya University
- National Cancer Center Research
Institute
- National Institute for Advanced
Interdisciplinary Research (NAIR)
- National Institute of Bioscience and
Human Technology
- Institute of Physical and Chemical
Research (RIKEN) Cell Bank
- Tokyo Institute of
Technology
- Tokyo Women's Medical
University
- University of Tokyo
- University of Tsukuba
D. Summary of the June 2000 U.S. Review
Workshop
Published: January 2002